Efficacy and Safety Study of SUNPG1623
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/17/2019 |
| Start Date: | May 17, 2017 |
| End Date: | May 15, 2020 |
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to
demonstrate the safety and efficacy of SUNPG1623
demonstrate the safety and efficacy of SUNPG1623
Inclusion Criteria:
- Subject has provided written informed consent
- Subject is ≥ 18 years of age at time of Screening
- Subject must be on stable dose of NSAID for ≥ 4 weeks prior to initiation of IMP
- Subject has a negative evaluation for TB within 4 weeks before initiating IMP
Exclusion Criteria:
- Subject has a planned surgical intervention between Baseline and the Week 24
evaluation for a pretreatment condition
- Subject has an active infection or history of infections
- Subject has any concurrent medical condition or uncontrolled, clinically significant
systemic disease
- Subject has a known history of infection with hepatitis B, hepatitis C, or human
immunodeficiency virus
We found this trial at
1
site
Click here to add this to my saved trials
